Serum FAP⁺ exosome-based flow cytometric detection: potential utility in early diagnosis, disease progression assessment, and surgical response monitoring of lung adenocarcinoma Authors: Ming Liu, Xiamin He, Jing Chen, Juan Huang, Xiang Lv, Guanghua Liu, Yijing Cai, Yanhui Lin, Yaocheng Wang, Yingying Cao, Minjian Huang, Rongzhao Zhang, Lilan Zhao, Jianlin Chen, Chundong Yu, Hao Zhang, Fangqin Xue, Yi Huang Published: 2026 ABSTRACT AbstractBackgroundLung adenocarcinoma (LUAD) remains a leading cause of cancer-related mortality, and currently available serum biomarkers have limited sensitivity and specificity for early diagnosis. We investigated whether serum fibroblast activation protein-positive (FAP⁺) exosomes could serve as a minimally invasive biomarker for LUAD.MethodsWe examined FAP expression and exosomal localization in cancer-associated fibroblasts (CAFs), evaluated a magnetic bead-based strategy for enriching FAP⁺ exosomes, and established a latex bead-based flow cytometric assay using biotinylated anti-FAP antibody and streptavidin-PE detection. The assay was then evaluated in healthy donors (HD), patients with benign lung lesions (LBL), and patients with LUAD, and its diagnostic performance was compared with conventional serum biomarkers, including CEA, NSE, and CYFRA21-1.ResultsExosomes released by CAFs showed elevated FAP expression, and FAP was associated with the exosomal marker CD9, supporting a possible CD9-associated exosomal sorting mechanism. In the clinical cohort, serum FAP⁺ exosome levels were significantly higher in LUAD than in HD and LBL, and increased with disease stage. In early-stage LUAD, serum FAP⁺ exosomes showed favorable diagnostic performance, with an AUC of 0.932, 88.4% sensitivity, and 87.6% specificity. Compared with conventional serum biomarkers, including CEA, NSE, and CYFRA21-1, serum FAP⁺ exosomes showed superior diagnostic performance in this cohort, while combined biomarker models provided only modest incremental improvement over FAP⁺ exosomes alone. Serum FAP⁺ exosome levels also decreased significantly after surgery, suggesting that this marker may reflect early postoperative changes.ConclusionThis study provides evidence that FAP is enriched in exosomes released by CAFs and may be incorporated into exosomes through a CD9-associated mechanism. We further established a serum FAP⁺ exosome-based flow cytometric assay that may serve as a promising minimally invasive strategy for LUAD diagnosis, disease progression assessment, and early postoperative monitoring.Graphical Abstract Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1186/s12951-026-04695-6.Keywords: Lung adenocarcinoma, Cancer-associated fibroblasts, Fibroblast activation protein, Exosomes, Liquid biopsy Introduction Lung adenocarcinoma (LUAD) is one of the most common subtypes of lung cancer and remains a leading cause of cancer-related death worldwide [1, 2]. Due to subtle early symptoms and rapid progression, approximately 60% of LUAD patients are diagnosed at an advanced stage, with a dismal 5-year survival rate of 15%−20% [3]. Despite advances in treatments, including immunotherapy, chemotherapy, surgery, and molecular-targeted therapy [4–6], the prognosis of LUAD patients remains poor. However, current tumor markers including CEA for LUAD suffer from the limitations of low sensitivity and inadequate specificity for early diagnosis [7]. Therefore, identifying informative biomarkers and developing efficient detection methods remain crucial for improving early diagnosis and clinical management of LUAD. As lipid-bilayer vesicles with diameters ranging from 30 to 150 nm, exosomes are widely present in various body fluids, including blood and urine, and released by multivesicular bodies fusing with the cell membrane [8–10]. In malignancies, exosomes regulate immune responses, facilitate epithelial-mesenchymal transition, and promote angiogenesis, all of which facilitate tumor growth and metastasis [11–14]. Notably, compared with normal tissues, tumor tissues may release increased numbers of exosomes into the peripheral circulation [15]. As enriched in functional biomolecules such as proteins and miRNAs, exosomes are considered a promising source of non-invasive biomarkers for precise management of malignancies [16, 17]. However, determining the specific cellular origin of serum exosomes remains challenging, as they can be secreted by diverse cell types systemically, thus limiting the effective utility of exosomes in tumor liquid biopsy. Cancer-associated fibroblasts (CAFs) present the most abundant stromal cell population in the tumor microenvironment (TME) [18]. Exosomes secreted by CAFs have been well documented to act as key effector molecules, mediating malignant tumor phenotypes and TME remodeling [19–21]. FAP, a transmembrane serine protease with dipeptidyl peptidase and gelatinase activities, is preferentially expressed by activated fibroblasts within the tumor microenvironment and is commonly enriched in CAFs across multiple epithelial malignancies [22–24]. FAP represents a useful marker associated with activated CAFs, as its expression is relatively low or undetectable in many resting normal fibroblasts but is frequently upregulated in CAFs in epithelial-derived malignancies, including lung, gastric, and colorectal cancers [25, 26]. During exosome biogenesis, multivesicular bodies fuse with the plasma membrane, enabling the transfer of specific membrane proteins from parental CAFs to the exosomal membrane [27, 28]. However, whether FAP is present on the membrane of CAF-derived exosomes and whether circulating serum FAP⁺ exosomes can be used as clinically informative biomarkers for LUAD remain unclear. In this study, we first investigated the membrane localization of FAP in CAF-derived exosomes and explored its possible association with CD9. We then developed a latex bead-based flow cytometric assay for the enrichment and semi-quantitative detection of serum FAP⁺ exosomes and evaluated its potential utility for LUAD diagnosis, disease progression assessment, and monitoring of early postoperative changes. Materials and methods Research subjects This study was approved by the Ethics Committee of the Fuzhou University Affiliated Provincial Hospital. All procedures were conducted in accordance with the Declaration of Helsinki and relevant ethical guidelines. Patients with lung adenocarcinoma (LUAD) who received treatment at the Fuzhou University Affiliated Provincial Hospital between January and December 2023 were consecutively enrolled. The diagnosis of LUAD was histopathologically confirmed by surgical resection or biopsy specimens. Clinical and imaging evaluations were used for disease assessment and staging when appropriate. Peripheral blood samples were collected prior to treatment initiation, and postoperative paired samples were additionally obtained from a subset of surgically treated patients. Tumor staging was classified according to the 8th edition of the Union for International Cancer Control (UICC) Tumor-Node-Metastasis (TNM) staging system. In addition, patients with benign lung lesions (LBL), excluding pulmonary fibrosis, as well as healthy donors (HD) undergoing routine physical examinations at the same institution, were enrolled as control groups. All participants had complete clinical records, and written informed consent was obtained from each participant prior to sample collection. Detailed de-identified clinical information for all enrolled participants, including demographic characteristics, clinical diagnosis, TNM classification and disease stage for LUAD patients, conventional serum tumor biomarkers, and serum FAP⁺ exosome positivity rates, is provided in Supplementary Table S1. Blood sample collection and processing Following an overnight fast of 12–14 h, 5 mL of venous blood was collected from each participant into vacuum blood collection tubes in the early morning. After standing at room temperature for 30 min, the samples were centrifuged at 3000 rpm and 4 °C for 15 min. The serum supernatant was transferred into Eppendorf tubes and stored at −80 °C until analysis. Samples with visible lipemia or hemolysis, as well as samples subjected to repeated freeze–thaw cycles, were excluded. Isolation and culture of fibroblasts associated with tumors Tumor and adjacent non-tumor tissues were obtained from LUAD patients undergoing surgical resection at the Department of Thoracic Surgery, Fuzhou University Affiliated Provincial Hospital. After being washed and cut into 1–2 mm³ pieces, the tissue fragments were subjected to centrifugation, filtration, and tissue enzyme digestion. The tissue fragments were then cultured in DMEM/F-12 medium supplemented with 10% fetal bovine serum. After incubation at 37 °C in a humidified atmosphere of 5% CO₂ for 48 h, the culture medium was replaced. When cells reached 70% confluence, they were passaged. To isolate primary fibroblasts, non-adherent cells were discarded 2–3 h after passaging. Subsequently, the adherent CAFs and paired NFs were further passaged and cultured. Isolation of cellular and serum-derived exosomes Primary fibroblasts were seeded into T75 flasks. At 70%−80% confluence, cells were washed and cultured in serum‑free medium for 24 h. Conditioned medium and serum samples were centrifuged, filtered through 0.22 μm membranes, and subjected to exosome isolation using EXODUS technology [29]. Purified exosomes were resuspended in DPBS and stored at −80 °C. All DPBS was pre‑filtered. Western blotting (WB) Cells were lysed on ice for 30 min with non-denaturing lysis buffer containing protease/phosphatase inhibitors. After centrifugation at 12,000 g and 4 °C for 15 min, supernatants were harvested and quantified by BCA assay. Proteins were denatured, separated via electrophoresis, transferred to PVDF membranes, and blocked with 5% non-fat milk at room temperature for 1 h. Membranes were incubated with primary antibodies at 4 °C overnight, washed, then incubated with HRP-conjugated secondary antibodies. Protein bands were visualized by ECL and analyzed densitometrically. Co-immunoprecipitation (Co-IP) Cells were lysed on ice for 30 min in non-denaturing lysis buffer containing protease/phosphatase inhibitors. After centrifugation at 12,000 g and 4 °C for 15 min, the supernatant was collected, with 10% reserved as Input. It was incubated with 2–5 µg primary antibody overnight at 4 °C, then with 50 µL Protein A/G agarose beads for 1–2 h. After washing thrice with IP buffer, the samples were mixed with 2×SDS loading buffer, boiled for 10 min and centrifuged. The supernatant was used for Western blot analysis with Input as control. Immunofluorescence Logarithmic growth phase cells were seeded into laser confocal dishes. At 70%−80% confluence, cells were fixed with 4% paraformaldehyde, permeabilized with 0.1% Triton X-100, and blocked with 5% BSA. After incubation with primary antibody at 4 °C overnight, cells were incubated with fluorescent secondary antibody in the dark, stained with DAPI, mounted with anti-fade medium, and observed via laser confocal microscopy. Transmission electron microscopy (TEM) A 20 µL exosome sample was mixed with 20 µL of 4% paraformaldehyde and placed on a hydrophobic paraffin membrane. Formvar‑coated copper grids were floated on the mixture for 20 min. After removing excess liquid, the grids were air‑dried for 1 h, counterstained with 2% uranium acetate for 30 s, and re‑dried. Finally, the grids were observed and imaged under a transmission electron microscope at 80 kV. Immunogold electron microscopy Copper meshes were pretreated as described in Sect. "Transmission Electron Microscopy (TEM)". After blocking in 1% BSA-PBS for 30 min, the meshes were incubated with rabbit anti-human FAP primary antibody at 4 °C overnight, then washed three times with 0.05% Tween-20 PBS. Following incubation with colloidal gold-labeled secondary antibody, the meshes were rinsed with deionized water, negatively stained with 2% uranium acetate, air-dried, and observed by transmission electron microscopy at 80 kV. Nanoparticle tracking analysis (NTA) Exosome samples were diluted with 1×PBS to achieve 20–100 particles per frame. After instrument parameter setup, diluted samples were automatically injected via a micropump. Six 30-s videos were recorded, and data were analyzed with NTA 3.4 software at a detection threshold of 5. The particle concentration and size distribution of exosomes were then determined. Measurement of conventional serum tumor biomarkers Serum conventional tumor biomarkers, including carcinoembryonic antigen (CEA), neuron-specific enolase (NSE), and cytokeratin 19 fragment (CYFRA21-1), were measured in the Department of Clinical Laboratory using routine automated immunoassay platforms according to the manufacturers’ instructions and standard clinical laboratory procedures. Preparation of anti-FAP rabbit monoclonal antibody New Zealand white rabbits were immunized with FAP protein, and antibody titers were determined after repeated immunization. Peripheral blood PBMCs were isolated following the third immunization, and single B cells were sorted by flow cytometry. High‑affinity positive clones were screened via ELISA and sequenced. After codon optimization and signal peptide modification, the sequence was used to construct an expression vector and transfected into CHO cells. The target antibody was purified from the fermentation broth using the AKTA Pure system and verified by electrophoresis and spectrophotometry. Preparation of anti-FAP antibody-conjugated magnetic beads Carboxyl magnetic beads were washed with 0.1 M MES buffer (pH 5.5) and activated using EDC/Sulfo-NHS at 25 ℃ for 1 h. The activated beads were resuspended in 0.1 M carbonate buffer (pH 9.5) and conjugated with anti-FAP rabbit monoclonal antibody (1 mg beads: 20 µg antibody) at 25 ℃ in the dark for 2 h. After blocking with 0.5% BSA in PBS (pH 7.4) at 37 ℃ for 2 h, the beads were washed, resuspended at 2 mg/mL, and stored sealed at 2–8 °C until use. Capture of serum exosomes using anti-FAP antibody-conjugated magnetic beads One milliliter of serum was centrifuged at 12,000 r/min at 4 °C for 15 min to remove cell debris, and the supernatant was collected. Then, 250 µL of anti-FAP antibody-conjugated magnetic bead suspension was added to a 1.5-mL EP tube and washed once with 500 µL PBST and twice with PBS. The serum supernatant was gently mixed with the bead suspension and incubated at 37 °C for 30 min. After magnetic separation, the supernatant was collected as the uncaptured fraction, and the bead-bound fraction was washed three times with PBS. The magnetic bead–exosome complexes were then resuspended in 30 µL PBS. To further estimate the capture efficiency of anti-FAP antibody-conjugated magnetic beads, total serum exosomes, captured exosome fractions, and uncaptured fractions from three representative LUAD samples were analyzed by Western blotting for FAP. Capture efficiency was calculated as captured FAP signal/(captured FAP signal + uncaptured FAP signal) × 100%. Preparation of anti-FAP antibody-biotin conjugates Anti-FAP rabbit monoclonal antibody was labeled with N-hydroxysuccinimide biotin. The reaction was performed in an appropriate buffer at an optimized ratio, allowing 3–5 biotin molecules to conjugate per antibody. Unbound biotin was removed by purification, yielding anti-FAP antibody-biotin conjugates with high specificity and labeling efficiency. The final conjugates were stored in the dark for subsequent experiments. Latex microsphere flow cytometry Quantified exosomes were incubated with 4 μm aldehyde/sulfate latex microspheres at room temperature for 20 min. The mixture was adjusted with DPBS and rotated at 4℃ overnight. After termination and blocking, samples were divided into three groups. The experimental group was incubated with biotinylated anti-FAP antibody, followed by streptavidin-PE staining in dark for 40 min. After washing, 50,000 events were analyzed by flow cytometry. A 1% PE-positive rate in the fluorescence control was used as the gating threshold. The PE-positive bead event rate was recorded as the FAP⁺ exosome positivity rate and used as a relative, semi-quantitative readout of serum FAP⁺ exosome abundance. Sample size calculation Prior to the formal experiment, a pilot study was conducted to assess intergroup variability of target indicators, with 10 HD, 10 patients with LBL, and 10 LUAD patients enrolled. One-way analysis of variance (ANOVA) was used to calculate the intergroup effect size of FAP⁺ exosome detection indicators (Cohen’s f = 0.45). Based on this effect size, we used the online sample size calculator (powerandsamplesize.com) with a two-tailed test, statistical power set at 80%, and significance level (α = 0.05). This estimated a minimum sample size of 35 per group to achieve the required statistical power. Finally, the study included 35 HD, 70 patients with LBL, and 93 LUAD patients with different TNM stages. The sample characteristics were consistent with clinical epidemiological features, fulfilling the sample size requirements for statistical analyses. Statistical analysis All data are presented as mean ± standard deviation (Mean ± SD) or median with interquartile range [M (P25, P75)]. Normality was assessed using the Shapiro-Wilk test. For normally distributed data, comparisons between two groups were performed using Student’s t-test, and comparisons among multiple groups were performed using one-way ANOVA followed by Bonferroni post hoc correction. For non-normally distributed data, the Mann-Whitney U test or Kruskal-Wallis test followed by Dunn’s multiple-comparison test was used, as appropriate. Paired preoperative and postoperative samples were analyzed using the paired t-test or Wilcoxon signed-rank test according to data distribution. Combined biomarker models were constructed using binary logistic regression, and the predicted probabilities were used for receiver operating characteristic (ROC) curve analysis. AUCs, 95% CIs, optimal cut-off values based on the Youden index, sensitivity, and specificity were calculated. A p < 0.05 was considered statistically significant. (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001) Results Exosomes released by CAFs exhibit elevated FAP expression To investigate exosomes derived from CAFs, we isolated primary cells and performed cell identification. Results verified the successful isolation of primary fibroblasts: both CAFs and NFs were negative for the leukocyte marker CD45 and endothelial marker CD31, whereas CAFs exhibited higher expression of fibroblast markers (FAP and α-SMA) compared with NFs (Fig. 1A). Exosomes were subsequently isolated from cell supernatants and characterized. Western blot confirmed successful exosome extraction: exosomal fractions expressed canonical exosomal markers CD9 and TSG101, but were negative for the endoplasmic reticulum marker Calnexin (Fig. 1B). Notably, exosomes released by CAFs displayed higher FAP expression levels than NF-derived exosomes, suggesting that FAP may be enriched in CAF-released exosomes. Immunogold transmission electron microscopy further verified the characteristic cup-shaped morphology of exosomes. FAP was localized to the external membrane of CAF-derived exosomes, whereas no significant FAP signal was detected on NF-derived exosomes (Fig. 1C). Characterization of CAF-released exosomes and evidence supporting a possible association between FAP and CD9. (A) WB validation of primary NFs and CAFs identification; (B) WB analysis of exosomal markers and FAP in NFs-Exo and CAFs-Exo, Calnexin excluded cellular contamination; (C) Immunogold TEM shows typical cup-shaped exosomes, with FAP on CAFs-Exo surface and no FAP on NFs-Exo; (D) Fluorescence microscopy and WB confirm FAP overexpression in CAFs-FAP-OE; (E) Volcano plot of IP-MS identifies CD9 as a key FAP-interacting protein; (F) Co-IP verifies FAP-CD9 interaction in CAFs, IgG as negative control; (G) IF shows colocalization of CD9 and FAP on the CAF plasma membrane FAP may be sorted to CAF-released exosomes through its interaction with CD9 To elucidate the molecular mechanism underlying FAP sorting to exosomes, we successfully constructed a CAF cell line stably overexpressing FAP via lentiviral transfection (Fig. 1D). FAP-interacting proteins were screened by IP-MS. Volcano plot analysis revealed marked enrichment of the exosomal marker CD9 among differentially expressed proteins, suggesting a potential interaction between FAP and CD9 (Fig. 1E). Direct physical binding between FAP and CD9 was validated by Co-IP assays: FAP was detected in CD9 immunoprecipitates and CD9 was reciprocally present in FAP immunoprecipitates (Fig. 1F). Immunofluorescence colocalization assays further confirmed prominent colocalization of CD9 and FAP in the cell membrane of CAFs, with substantial overlap of the two fluorescent signals (Fig. 1G). Collectively, these findings support the possibility that FAP may be sorted to CAF-released exosomes through its association with CD9, providing mechanistic support for serum FAP⁺ exosomes as promising diagnostic biomarkers for LUAD. Differential expression of serum FAP⁺ exosomes and development of an anti-FAP antibody-conjugated magnetic bead capture strategy To investigate FAP expression levels in circulating exosomes, we utilized the EXODUS platform to isolate serum exosomes from LUAD patients (Fig. 2A). Purity of the isolated exosomes was validated by WB, NTA, and TEM. Isolated particles displayed characteristic exosomal features: they were negative for the endoplasmic reticulum marker Calnexin, positive for canonical exosomal markers CD9 and TSG101, exhibited a typical cup-shaped morphology, and had a size distribution of 30–150 nm (Fig. 2B-D). Subsequently, we performed WB to assess FAP expression levels in serum exosomes from HD and LUAD patients. Exosomes from the LUAD group exhibited significantly higher FAP protein levels, whereas those from HD displayed minimal or undetectable FAP expression levels (Fig. 2E). To specifically enrich FAP⁺ exosomes from serum, we developed a targeted capture strategy using anti-FAP antibody-conjugated magnetic beads. The efficacy of this approach was confirmed by WB and TEM. TEM analysis after capture revealed abundant exosomes attached to the bead surface in the LUAD group, whereas only a few nonspecifically bound particles were observed in the HD group (Fig. 2F). Consistently, WB analysis further supported that anti-FAP antibody-conjugated magnetic beads could enrich FAP⁺ exosomes from serum. Densitometric quantification of FAP signals in the captured and uncaptured fractions showed capture efficiencies of 58.6%, 61.5%, and 64.4% in three representative LUAD samples, with a mean efficiency of 61.5 ± 2.9% (Fig. 2G). Collectively, these findings indicate that FAP can serve as a useful target for the detection and isolation of CAF-associated exosome subpopulations in LUAD. Characterization of serum FAP⁺ exosomes and validation of an anti-FAP antibody-conjugated magnetic bead capture strategy in LUAD. (A) Serum exosome extraction workflow; (B) Western blot analysis for serum exosome identification; (C) Particle size analysis of serum exosomes; (D) Transmission electron microscopy images of serum exosomes; (E) FAP expression levels in serum exosomes from LUAD patients and HD; (F) Electron microscopy image of serum exosomes captured by anti-FAP antibody-conjugated magnetic beads; (G) Western blot-based evaluation of the capture efficiency of anti-FAP antibody-conjugated magnetic beads Detection of serum FAP⁺ exosomes using an anti-FAP antibody-based flow cytometric assay We established a flow cytometric assay using anti-FAP antibody-biotin conjugates and latex beads to detect serum FAP⁺ exosomes (Fig. 3A). In this assay, the PE-positive rate represents a relative, semi-quantitative indicator of serum FAP⁺ exosome abundance. Non-specific binding was validated using a BSA-based non-target control, with comparable PE-positive rates in the anti-FAP treated (1.77%) and fluorescence control (1.01%) groups, confirming low non-specific binding (Fig. 3B). Assay specificity was verified in HD, where the mean PE-positive rate in the Anti-FAP treated group was significantly higher than in the isotype control (Fig. 3C). We further analyzed serum samples from patients with various LBL, including pulmonary infection (PI), benign pulmonary tumors/nodules (BPT/N), and pulmonary granulomatous lesions (PGL). Representative flow cytometric plots for each benign lesion subgroup are shown in Fig. 3D-F. Age and gender distributions were comparable among LUAD, LBL, and HD groups (Table 1). Patient-level de-identified clinical information is provided in Supplementary Table S1. There were no significant differences in serum FAP⁺ exosome positive rates among the three LBL subgroups, including PI (16.50% [11.63%, 27.85%]), BPT/N (22.60% [18.30%, 34.40%]), and PGL (24.40% [19.60%, 36.70%]) (Fig. 3H). However, the FAP⁺ exosome positive rates in these LBL subgroups were higher than those in HD (9.49% [4.88%, 13.50%]), especially in BPT/N and PGL groups (p < 0.05, p < 0.0001, p < 0.0001, respectively) (Fig. 3G). These results indicate that serum FAP⁺ exosome levels may also be elevated in certain LBL, particularly BPT/N and PGL. Detection of serum FAP⁺ exosome levels in HD and LBL subgroups using the flow cytometric assay. (A) Schematic of the FAP⁺ exosome flow cytometric assay using anti-FAP antibody-biotin conjugates and latex beads; (B) Validation of non-specific binding with a BSA control; (C) Representative FAP⁺ exosome detection plots in HD; (D-F) Representative plots in patients with PI, BPT/N, and PGL; (G) Scatter plot of FAP⁺ exosome positive rates across HD, PI, BPT/N, and PGL groups, showing higher levels in LBL subgroups than in HD, particularly in BPT/N and PGL groups (*p < 0.05, ****p < 0.0001); (H) Scatter plot comparing FAP⁺ exosome positive rates among PI, BPT/N, and PGL groups (ns, not significant) Table 1Baseline characteristics of the study cohortStudy cohortN (%)Patients with LUAD93 Age55.97 ± 11.53 Sex Male48 (51.61) Female45 (48.39) Stage Early-stage43 (46.24) Advanced-stage29 (31.18) Late-stage21 (22.58) CEA ≥ 5 ng/mL17 (18.28) < 5 ng/mL76 (81.72)Patients with LBL70 Age54.09 ± 10.37 Sex Male34 (48.57) Female36 (51.43) CEA ≥ 5 ng/mL0 (0) < 5 ng/mL70 (100)Healthy donors35 Age51.00 ± 9.17 Sex Male17 (48.57) Female18 (51.43) CEA ≥ 5 ng/mL0 (0) < 5 ng/mL35 (100) Baseline characteristics of the study cohort Serum FAP⁺ exosome positivity rates are elevated in LUAD patients We analyzed serum FAP⁺ exosome expression in patients with LUAD across different stages to evaluate its diagnostic utility. Representative flow cytometric plots showed higher FAP⁺ exosome positive rates in early-stage (stages 0 + I), advanced-stage (stages II + III), and late-stage (stage IV) LUAD patients (Fig. 4A-C). In the overall comparison, all-stage LUAD showed higher serum FAP⁺ exosome positive rates (53.00% [39.55%, 74.15%]) than HD (9.49% [4.88%, 13.50%]) and LBL (22.45% [18.09%, 34.15%]) (both p < 0.0001; Fig. 4D). Pairwise comparisons further showed that early-stage LUAD (40.20% [36.90%, 50.20%]), advanced-stage LUAD (53.80% [45.60%, 60.85%]), and late-stage LUAD (90.20% [82.10%, 95.55%]) were each significantly higher than HD and LBL (all p < 0.0001; Fig. 4E-G). Interstage comparisons showed that FAP⁺ exosome positive rates were higher in advanced-stage than in early-stage LUAD (p < 0.05), higher in late-stage than in advanced-stage LUAD (p < 0.0001), and higher in late-stage than in early-stage LUAD (p < 0.0001) (Fig. 4H). In 20 LUAD patients with paired samples, postoperative FAP⁺ exosome positive rates were significantly lower than preoperative levels (p < 0.0001, Fig. 4I-J), suggesting that serum FAP⁺ exosome detection may provide an early indication of postoperative change after surgical tumor removal. Serum FAP⁺ exosome levels in LUAD across disease stages and after surgery. (A-C) Representative flow cytometry histograms of serum FAP⁺ exosomes in early-, advanced-, and late-stage LUAD patients; (D) Relative semi-quantitative assessment of serum FAP⁺ exosome positive rates in HD, LBL, and all-stage LUAD. Pairwise comparisons showed that all-stage LUAD was significantly higher than HD and LBL; (E-G) Pairwise comparisons of serum FAP⁺ exosome positive rates between each LUAD stage and HD/LBL, including early-stage versus HD/LBL, advanced-stage versus HD/LBL, and late-stage versus HD/LBL; (H) Pairwise interstage comparisons showed significant differences between early- and advanced-stage LUAD, advanced- and late-stage LUAD, and early- and late-stage LUAD; (I) Paired analysis of serum FAP⁺ exosome positive rates before and after surgery in individual LUAD patients; (J) Comparison of serum FAP⁺ exosome positive rates before and after surgery, reflecting postoperative changes. *p < 0.05, ****p < 0.0001 Diagnostic efficacy of serum FAP⁺ exosomes and conventional serum biomarkers for LUAD We utilized ROC curves to define the diagnostic performances of serum FAP⁺ exosomes, CEA, and their combination across different stages of LUAD (vs. HD + LBL, Fig. 5A). Across all stages, FAP⁺ exosomes achieved an AUC of 0.962, higher than CEA (AUC = 0.644), with the combined marker yielding an AUC of 0.963. In early-stage LUAD, FAP⁺ exosomes (AUC = 0.932) outperformed CEA (AUC = 0.501), showing 88.4% sensitivity and 87.6% specificity versus CEA’s 30.2% and 85.7%. In advanced-stage LUAD, FAP⁺ exosomes had an AUC of 0.978 (CEA: 0.721), and in late-stage LUAD, an AUC of 1.000 (CEA: 0.832). Across all stages, FAP⁺ exosomes showed 94.6% sensitivity and 87.6% specificity, which were higher than those of CEA in this cohort (50.5% sensitivity and 84.8% specificity). Notably, combined detection did not improve diagnostic efficacy over FAP⁺ exosomes alone (Fig. 5B). Diagnostic performance of CEA, serum FAP⁺ exosomes, and their combined detection for LUAD across different disease stages. (A) ROC curves of CEA, serum FAP⁺ exosomes, and their combined detection for distinguishing LUAD patients at all stages, early stage, advanced stage, and late stage from the combined HD and LBL control population. Each curve is labeled with its AUC value. (B) Summary table of diagnostic performance metrics for CEA, serum FAP⁺ exosomes, and their combined detection across different LUAD stages. Metrics include AUC with 95% CI, optimal cut-off value, sensitivity, and specificity To further evaluate whether serum FAP⁺ exosome detection could complement routinely used serum biomarkers, we analyzed the diagnostic performance of NSE, CYFRA21-1, and their combinations with serum FAP⁺ exosomes across different LUAD stages. NSE alone showed modest diagnostic performance, with AUC values of 0.696 for all-stage LUAD, 0.668 for early-stage LUAD, 0.688 for advanced-stage LUAD, and 0.765 for late-stage LUAD (Fig. S1A-B). CYFRA21-1 alone showed similar performance, with AUC values of 0.665, 0.612, 0.683, and 0.749, respectively (Fig. S1C-D). In contrast, combinations incorporating serum FAP⁺ exosomes achieved consistently higher AUC values than conventional biomarkers alone. The combination of NSE and serum FAP⁺ exosomes yielded AUC values of 0.963, 0.933, 0.980, and 1.000 for all-stage, early-stage, advanced-stage, and late-stage LUAD, respectively (Fig. S1A-B). Similarly, CYFRA21-1 combined with serum FAP⁺ exosomes achieved AUC values of 0.964, 0.936, 0.979, and 1.000, respectively (Fig. S1C-D). The multi-marker model combining NSE, CYFRA21-1, CEA, and serum FAP⁺ exosomes showed AUC values of 0.965, 0.936, 0.983, and 1.000 across the corresponding stage groups (Fig. S1E-F). Although the incremental improvement over serum FAP⁺ exosomes alone was modest, these combined analyses indicated that serum FAP⁺ exosome detection maintained strong diagnostic performance in multi-marker models and outperformed conventional serum biomarkers alone in this cohort. These results suggest that serum FAP⁺ exosome positivity rate was the dominant contributor to the diagnostic performance of the combined models in this cohort, whereas conventional biomarkers provided only limited incremental improvement. Discussion LUAD remains a major cause of cancer-related mortality worldwide [2], and insufficient sensitivity of currently available serum biomarkers continues to limit early diagnosis and disease monitoring [30, 31]. In recent years, exosome-based liquid biopsy has attracted increasing attention because of its non-invasive nature, repeatability, and ability to reflect tumor-associated biological alterations [32, 33]. As key targets in liquid biopsy, exosomes have provided new opportunities for the precise diagnosis and clinical management of LUAD [34–36]. Previous studies have demonstrated the diagnostic potential of circulating small extracellular vesicle-derived molecules in LUAD, including RNA-based signatures with high diagnostic accuracy [37]. In the present study, we focused on serum FAP⁺ exosomes, a vesicle subpopulation likely enriched in CAF-associated exosomes because FAP is highly expressed in activated CAFs within the TME. We further explored a potential CD9-associated mechanism for FAP localization on exosomal membranes and established a latex bead-based flow cytometric assay for serum FAP⁺ exosome detection. Collectively, our study provides supportive evidence that FAP can be enriched on CAF-released exosomal membranes, develops a semi-quantitative flow cytometric strategy for detecting serum FAP⁺ exosomes, and demonstrates the potential clinical relevance of this marker in LUAD diagnosis and monitoring. CAFs are pivotal components of the TME and contribute to tumor progression, metastasis, immune modulation, and extracellular matrix remodeling through the secretion of cytokines, extracellular vesicles, and other bioactive mediators [38, 39]. FAP is a characteristic membrane-associated marker of activated CAFs and has been implicated in tumor invasion, metastasis, and unfavorable clinical outcomes across multiple malignancies [40–42]. In this study, CAF-released exosomes exhibited higher FAP expression than NF-released exosomes, and immunogold electron microscopy further supported the localization of FAP on the surface of CAF-released exosomes. These findings suggest that FAP may be useful for enriching CAF-associated exosome subpopulations. However, given the heterogeneous cellular origins of circulating exosomes, serum FAP⁺ exosomes should be considered CAF-associated rather than CAF-exclusive. CD9 is a representative tetraspanin involved in exosome biogenesis, membrane organization, and cargo sorting [43, 44]. Our results showed an association between FAP and CD9 and their colocalization in CAFs, suggesting that CD9 may contribute to the enrichment of FAP on CAF-associated exosomal membranes. Efficient enrichment and detection of disease-relevant exosome subpopulations remain major challenges for the clinical translation of circulating exosome biomarkers [45]. Several advanced immunoaffinity-based and nanotechnology-assisted platforms have been developed to improve the detection and molecular profiling of circulating EVs. For example, ExoScreen enables sensitive detection of disease-associated circulating EVs using antibody-based recognition without prior EV purification [46]. Nano-plasmonic exosome sensing platforms further allow label-free, high-throughput, and quantitative molecular profiling of exosomes [47]. In addition, multiparametric plasma EV profiling based on multiplexed plasmonic assays has demonstrated the diagnostic value of tumor-derived EV surface protein signatures in clinical cancer samples [48]. Microfluidic EV platforms also offer advantages such as low sample consumption and integrated analysis. However, many of these advanced platforms still require specialized devices, optimized antibody panels, or standardized analytical workflows, which may limit their immediate implementation in routine clinical laboratories. Conventional immunocapture-based ELISA assays are plate-compatible and suitable for parallel detection but usually provide bulk-level signals and may not easily resolve marker-positive EV subpopulations. Magnetic immunocapture can selectively enrich EV subsets for downstream analysis, although its performance depends on antibody coupling efficiency, bead properties, washing conditions, and elution or detection workflows. The assay developed in this study directly targets the FAP-positive exosome subpopulation using biotinylated anti-FAP antibody recognition combined with latex bead-based flow cytometric detection. This strategy may reduce interference from FAP-negative circulating exosomes and improve the biological relevance of the detected signal to LUAD-associated stromal remodeling. In addition, latex microsphere coupling and biotin-streptavidin signal amplification facilitate flow cytometric detection of FAP⁺ exosome-associated signals. Nevertheless, the current assay provides a relative, semi-quantitative readout based on PE-positive bead events rather than an absolute concentration of circulating FAP⁺ exosomes. Clinically, serum FAP⁺ exosome levels were significantly higher in LUAD patients than in HD and LBL controls and increased progressively with disease stage, suggesting a potential association with tumor burden and disease progression. ROC analysis further showed that serum FAP⁺ exosomes had favorable diagnostic performance for LUAD, particularly in early-stage disease, with an AUC of 0.932, 88.4% sensitivity, and 87.6% specificity. Compared with conventional serum biomarkers, including CEA, NSE, and CYFRA21-1, serum FAP⁺ exosomes showed more favorable diagnostic performance than conventional serum biomarkers in this cohort. Although combined models incorporating serum FAP⁺ exosomes achieved higher AUC values than conventional biomarkers alone, the improvement over serum FAP⁺ exosomes alone was limited, suggesting that serum FAP⁺ exosomes may be the main contributor to the diagnostic performance of these models. Nevertheless, serum FAP⁺ exosome elevation should not be considered completely LUAD-specific. Serum FAP⁺ exosome levels were also increased in some LBL subgroups, which may reflect fibroblast activation associated with chronic inflammation, granulomatous reactions, tissue remodeling, or fibrotic repair. Notably, serum FAP⁺ exosome levels remained significantly higher in LUAD than in LBL, and ROC analysis demonstrated favorable performance in distinguishing LUAD from the combined HD and LBL control population. In addition, the significant postoperative decrease in serum FAP⁺ exosome levels in paired LUAD samples suggests a potential role for this marker in early postoperative monitoring. Several limitations should be acknowledged. First, serum FAP⁺ exosome levels were mildly elevated in some LBL, and the present cohort did not include other cancer types, different lung cancer histological subtypes, or fibrotic diseases. Therefore, the disease specificity of serum FAP⁺ exosomes requires further validation in larger, multicenter prospective cohorts with broader disease controls. Second, the current flow cytometric assay remains a relative, semi-quantitative method rather than an analytically validated quantitative platform, and has not yet been integrated with a standardized calibration system. Therefore, analytical sensitivity, limit of detection, linear range, batch-to-batch reproducibility, and inter-laboratory consistency could not be fully determined in the present study. Future studies should establish standardized calibrators, unified gating criteria, and reproducibility assessment procedures to support clinical translation. Third, although Co-IP, cellular colocalization, and exosomal membrane localization analyses support a potential association between FAP and CD9, direct visualization of FAP/CD9 dual-marker colocalization on individual exosome membranes was not performed. Future studies using double immunogold TEM, single-vesicle imaging, or other high-resolution approaches will be needed to further validate the colocalization of FAP and CD9 on CAF-released exosomes. Finally, this study only evaluated short-term postoperative changes in serum FAP⁺ exosome levels and lacked long-term follow-up data. Therefore, the postoperative decrease observed in this study should be interpreted as an early postoperative change rather than definitive evidence of long-term therapeutic efficacy. The value of serum FAP⁺ exosomes for recurrence prediction, survival assessment, longitudinal treatment monitoring, and integration with exosomal molecular cargo warrants further investigation. Conclusions This study provides evidence that FAP is enriched in CAF-released exosomes and may be incorporated into exosomes through a CD9-associated mechanism. We further established a serum FAP⁺ exosome-based flow cytometric assay that may provide a promising minimally invasive approach for LUAD diagnosis, disease progression assessment, and monitoring of early postoperative changes. Supplementary Information Supplementary Material 1 Supplementary Material 2 Acknowledgements Not applicable. Author contributions ML, XMH, JC, JH contributed equally to this work. ML, XMH, JC and JH conducted all experiments and wrote the original draft. XL, GHL, YJC, and YHL collected serum samples. YCW, YYC and MJH analyzed data. RZZ, LLZ and JLC provided experiment assistance. YH, FQX, HZ and CDY performed manuscript revisions and handled project administration. All authors approved the final version before submission. Funding This study was supported in part by Fujian Province’s Joint Fund for Science and Technology Innovation (Grant No. 2021Y9024) to Yi Huang, Fujian Province’s Key Project of the Natural Science Foundation (Grant No. 2022J02048) to Yi Huang, Industry-University Cooperation Projects in Fujian Province (Grant No. 2025Y4011) to Yi Huang, Medical Vertical Project of Fujian Province (Grant No. 2025CXA002) to Yi Huang, Project of the Department of Finance of Fujian Province (Grant No. 2024061) to Yi Huang, Fujian Provincial Health Technology Project (Grant No. 2024ZD01001) to Fangqin Xue, the Major Science and Technology Project of Fujian Province (Grant No. 2024YZ034026) to Fangqin Xue, Natural Science Foundation of Fujian Province (Grant No. 2025J011328) to Jing Chen. Data availability The datasets used and analyzed during the current study are available from the corresponding author on reasonable request. Declarations Ethics approval and consent to participate This study was sought and approved by the Ethics Committee of Fuzhou University Affiliated Provincial Hospital (Ethics Approval Number K2018-12-040/02). Informed consent was obtained from all subjects or their legal guardian(s). All methods were carried out in accordance with relevant guidelines and regulations. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Ming Liu, Xiamin He, Jing Chen and Juan Huang contributed equally to this work. Contributor Information Chundong Yu, Email: cdyu@xmu.edu.cn. Hao Zhang, Email: haolabcancercenter@163.com. Fangqin Xue, Email: xuefangqingsl@sina.com. Yi Huang, Email: hyi8070@126.com. References Associated Data Data Availability Statement The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.